Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE iRhythm Technologies, Inc.
SAN FRANCISCO, May 12, 2014 /PRNewswire/ -- iRhythm Technologies, Inc., a healthcare information services company, today announced that data from four studies presented recently at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions, support the use of the company's ZIO Service to identify atrial fibrillation (AF) and other cardiac arrhythmias.
AF is the most common type of arrhythmia, affecting nearly 2.7 million people in the United States. Data show that AF elevates a patient's risk of ischemic stroke by five times, making its timely diagnosis critical so that proper treatment may be initiated. The ZIO Service enables long-term continuous monitoring – using a novel, small, wearable patch – to detect AF and other episodic heart rhythm disturbances that are often challenging to identify using current methods.
"We presented two studies evaluating the ZIO Patch in real world situations," said Mintu Turakhia, MD MAS, assistant professor at Stanford University. "In the first study, we found that conversion to the ZIO Patch, worn on average for 11 days, compared to traditional monitors, worn on average for one day, was associated with increased yield of atrial fibrillation, which can cause stroke if untreated. In the second study, we found that in one out of every nine subjects who had heart disease but no history of arrhythmias, the ZIO Patch detected arrhythmias that may lead to stroke, even though the subjects had no awareness of them. These findings underscore the importance of extended monitoring and the potential value of screening for silent heart rhythm disorders."
The following abstracts were presented at Heart Rhythm 2014:
"These new studies add to the growing body of evidence establishing the clinical performance and utility of the ZIO Service to improve diagnosis of patients with suspected cardiac arrhythmias," said Kevin King, president and chief executive officer of iRhythm. "They also underscore the increasing recognition among physicians of the ZIO Service as the new standard of care for ambulatory cardiac monitoring of patients."
Another abstract presented at the meeting was:
About the ZIO Service
The ZIO Service, comprised of the ZIO Patch, proprietary algorithms and the ZIO Report, is proven in multiple, peer-reviewed published studies to produce a higher diagnostic yield and to change patient management, compared to traditional approaches to ambulatory electrocardiogram (ECG) monitoring. The ZIO Patch is a noninvasive, water-resistant monitor that is easy to use and discrete to wear, and is worn for up to 14 days, prompting high patient compliance and a higher diagnostic yield. Proprietary algorithms analyze the vast amounts of captured heart beat data and a concise report is provided to the patient's physician. Since its commercial launch in 2011, the ZIO Service has been used with more than 200,000 patients at nearly 800 institutions nationwide. The ZIO Service is covered for most Medicare patients and by leading private payers nationwide, representing more than 180 million covered lives.
About iRhythm Technologies, Inc.
iRhythm is a privately held healthcare information services company that aspires to be the world leader in the management of cardiac arrhythmia information, a large and growing unmet clinical need. Its flagship solution, the ZIO Service, offers a proven approach to long-term continuous monitoring that enables diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs. For more information, please visit www.irhythmtech.com.
©2012 PR Newswire. All Rights Reserved.